Drug intelligence / Profile preview

SP0342

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SP0342 is an adjuvanted subunit vaccine candidate being developed by Sanofi in collaboration with Amgen for the prevention of shingles (herpes zoster). It is designed to elicit a robust immune response against the varicella-zoster virus (VZV) by utilizing a specific viral protein (subunit) combined with an adjuvant to enhance immunogenicity. The vaccine is currently in Phase 1 clinical development, aiming to provide a protective alternative to existing shingles vaccines by inducing high levels of antigen-specific antibodies and T-cell responses.

Other names: Subunit adjuvanted vaccine (Shingles)

Beyond the preview

Go deeper on SP0342.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP0342.

Explore the full profile